Study of Serum Endocan and Copeptin Levels in Preterm Babies With Respiratory Distress Syndrome Between 28 and 36 Weeks of Gestation

What this Trial Is About

Researchers are investigating and comparing the levels of serum endocan and serum copeptin in preterm newborns diagnosed with respiratory distress syndrome RDS. This study aims to understand how these levels on the first day of life relate to the severity of respiratory distress. Respiratory distress in preterm infants is a significant challenge due to its high risks and impact on families and healthcare. The study involves measuring serum endocan and serum copeptin using enzyme-linked immunosorbent assay ELISA tests on the first day of life. Participants include preterm neonates grouped by gestational age between 28 and 34 weeks and between 34 and 36 weeks. These measurements will help compare the two biomarkers levels and their association with RDS severity. During the study, blood samples will be taken from the neonates on the first day of life to assess serum endocan and copeptin levels. The researchers will also monitor copeptin levels again on the fifth day of life. The main focus is to predict the severity of respiratory distress syndrome and possible mortality outcomes. The participation period covers the first few days after birth with specific biomarker assessments to support clinical understanding.

Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome